0001398733-26-000018
SEC filingAquestive Therapeutics reported a net loss of $83.8 million for fiscal year 2025, driven by total costs and expenses of $115.6 million which significantly exceeded revenues of $44.5 million. The company generated negative operating cash flow of $52.4 million, though financing activities provided $102.6 million primarily from equity offerings, resulting in a net cash increase of $49.6 million and year-end cash of $121.2 million. Key challenges include the CRL received for Anaphylm in January 2026 requiring additional clinical work, the conversion of Libervant approval to tentative status following litigation, and upcoming debt obligations with $45 million in 13.5% Notes requiring principal payments starting June 2026. Revenue declined from prior years due to sunsetting Suboxone sales, with Indivior representing 73% of total revenue.
Aquestive Therapeutics reported significant financial challenges for fiscal year 2025 with revenue of $44.5 million and a net loss of $83.8 million. The company's total costs and expenses reached $115.6 million, comprising manufacturing and supply costs of $18.6 million, research and development expenses of $17.2 million, and selling, general and administrative expenses of $79.8 million. Interest expenses totaled $17.0 million including $11.1 million in regular interest, $5.7 million related to royalty obligations, and $243,000 related to sale of future revenue. The company ended the year with $121.2 million in cash and cash equivalents, though operating activities used $52.4 million in cash.
Revenue of $44.5 million represents continued decline from the sunsetting Suboxone product, which faces generic competition. The company noted that Indivior accounted for approximately 73% of total revenue for 2025, creating significant customer concentration risk. Other revenue streams include Sympazan (licensed to Assertio), Ondif in Brazil, and Emylif in the EU. The company's proprietary product pipeline remains in development with Anaphylm receiving a Complete Response Letter in January 2026 and Libervant having its approval converted to tentative status following litigation.
The company reported negative operating margin with loss from operations of $71.1 million on revenue of $44.5 million. Gross margin information is not explicitly provided in the XBRL data, but the manufacturing and supply costs of $18.6 million against $44.5 million revenue suggests significant margin pressure. Selling, general and administrative expenses of $79.8 million represented the largest cost component, exceeding revenue by $35.3 million. Research and development expenses of $17.2 million reflect continued investment in the product pipeline despite financial constraints.
Operating activities used $52.4 million in cash, primarily due to the net loss of $83.8 million offset by non-cash adjustments including share-based compensation of $7.6 million and amortization of debt costs of $11.0 million. Investing activities used $562,000 for capital expenditures. Financing activities provided $102.6 million primarily from equity offerings including $79.5 million from public offerings and $21.2 million from ATM facilities. The balance sheet shows total assets of $160.4 million against total liabilities of $194.1 million, resulting in stockholders' deficit of $33.7 million. Debt includes $45 million in 13.5% Notes requiring principal payments starting June 2026.
The company faces significant challenges including the need to address FDA concerns raised in the Anaphylm CRL, which requires additional human factors studies and clinical trials. Management must also manage upcoming debt obligations with $45 million in 13.5% Notes requiring quarterly principal payments starting June 2026 unless refinanced. The company has $78 million remaining in its ATM facility as of December 31, 2025. Key risk factors include dependence on Indivior for 73% of revenue, need for substantial additional capital to commercialize Anaphylm if approved, and competitive pressures in all target markets. The company expects to continue incurring net losses for the foreseeable future.